Impact of the International Reference Pricing on Pharmaceutical Market Access
International reference pricing (IRP) is a process of cost comparison through external reference or cross-reference, which is used by many multinational pharmaceutical companies located in the States of the European Union. The IRP process has been reinforced through the process of mutual recognition of innovative drugs in 1975, the creation of an internal market in the European Union in 1992, and the institution of the European Medical Agency (EMA) in 1995 [1]. Compared to other models, which are based on the evaluation of costs, profits and effectiveness of drugs (value-based pricing), the IRP is a simple process [2].